Navigating GMO Landscape following the EU Clinical Trial Regulation 536/2014 implementation

In a rapidly evolving regulatory environment, understanding the EU GMO landscape is crucial for biotech and pharma companies navigating clinical trials.

 
Ergomed’s recent webinar, now available on demand, provides expert guidance on the latest GMO requirements within the centralized CTA submission framework under EU Clinical Trial Regulation 536/2014.
  Key Takeaways Include:
  • Understanding GMOs and GMMs
  • Overview of the EU GMO legal framework
  • Conducting GMO environmental risk assessments for GTMPs
  • GMO considerations under CTR (EU) No 536/2014

"*" indicates required fields

Please enter your details to get access to the resource

By submitting this form, you consent to your personal data submitted in the form being processed in alignment with our Online Privacy and Cookies policy. Your personal data will be processed to facilitate your request and may be used for sending you additional marketing and business development-related information about Ergomed, its affiliates, and our services. You can withdraw your consent anytime by messaging marketing@ergomedgroup.com, and we will promptly remove your data from our records. For more information about how we will process your personal data and your rights, please see our Online Privacy and Cookies policy.
This field is for validation purposes and should be left unchanged.